

Referral Status:	MRN:
<input type="checkbox"/> New referral	<input type="checkbox"/> Order change
<input type="checkbox"/> Patient preferred clinic:	<input type="checkbox"/> Order Renewal

Ultomiris™ (ravulizumab) Standard Plan of Treatment

PATIENT DEMOGRAPHICS:

Date of Referral:	Patient's Phone:
Patient Name:	Address:
Date of Birth:	City, State, Zip:
Height in inches:	Weight: LB or KG
Gender:	Allergies:
<input type="checkbox"/> See list	<input type="checkbox"/> NKDA

DIAGNOSIS: (PLEASE COMPLETE 2ND AND 3RD DIGITS TO COMPLETE ICD 10 FOR BILLING)

D59.5 - Paroxysmal nocturnal hemoglobinuria	G70.01 - Myasthenia Gravis with acute exacerbation
D59.30 - Hemolytic Uremic Syndrome	G70.00 - Myasthenia Gravis without acute exacerbation
- Other:	

REQUESTED DOCUMENTATION:

1 Insurance information	IF NO:	IF YES:
2 History & Physical/Tried and failed therapies	PLEASE STATE REQUIRED WASHOUT FROM PREVIOUS THERAPY:	LAST INFUSION DATE:
3 Full medication list		NEXT INFUSION DATE:
4 REQUIRED: Documentation of meningococcal vaccine (MenACWY AND MenB) at least 2 weeks prior to start of therapy		IF ORDER CHANGE:
		Continue current order until insurance approved

MEDICATION ORDERS:

NOTE: Patient may be ineligible to receive ravulizumab if receiving antibiotics for active infectious process, antifungal therapy, active fever and/or suspected infection, presents with any symptoms of meningococcal infections, and/or surgery.

PREMEDICATION TO BE ADMINISTERED 30 MINUTES PRIOR TO ADMINISTRATION AS SELECTED

IV	Diphenhydramine	25mg	50mg		PO	Acetaminophen	325mg	500mg	650mg	1000mg
	Methylprednisolone	40mg	125mg	Other:		Famotidine	20mg	40mg		
	Famotidine	20mg	40 mg			Diphenhydramine	25mg	50mg		
	Other:					Fexofenadine	60mg	180mg		
					Cetirizine	10mg				
					Loratadine	10mg				
					Other:					

MEDICATION:

Ultomiris™ (ravulizumab) dose to be diluted in NS for a final concentration of 50mg/ml. Infused via IV per protocol. Flush entire line with 25ml NS at the end of the infusion.

DOSE (INDUCTION/MAINTENANCE):

Dose per guidelines from the following FDA package labeling			
Patient Body Weight	Initial Dose	Maintenance Dose/Interval	
40kg to less than 60kg	2400mg	3000mg	every 8 weeks
60kg to less than 100kg	2700mg	3300mg	
100kg or greater	3000mg	3600mg	

FREQUENCY (INDUCTION/MAINTENANCE):

Loading dose at week 0 followed by maintenance dose at week 2 and every 8 weeks thereafter.

Maintenance dosing every 8 weeks

Other: _____

Follow each infusion with a 1-hour post observation.

SUPPLEMENTAL DOSING:

Within 4 hours of an IVIG cycle, dose 600mg Ultomiris™

Other Supplemental Dosing: _____

Administration: Ultomiris™ (ravulizumab) supplemental dose to be diluted in NS to a final concentration of 50mg/mL and infused via IV per protocol. **Prime line with 25mL of NS before supplemental dose.** Flush entire line with 25mL of NS at the end of the infusion.

SPECIAL/LAB ORDERS:

Refills x 12 months unless noted otherwise here:

Ultomiris™ (ravulizumab) is restricted to credentialed prescribers enrolled in the Ultomiris (REMS) program.

LINE USE/CARE ORDERS:

Start PIV/Access CVC

Flush device per facility standard flushing procedure

Provide nursing care per Palmetto Infusion Nursing Procedures and post procedure observation if indicated

ADVERSE REACTION & ANAPHYLAXIS ORDERS:

Administer acute infusion and anaphylaxis medications per Palmetto Infusion standing adverse reaction orders, which can be found at our website or scan here.



PRESCRIBER INFORMATION:

PROVIDER NAME:	PHONE:
ADDRESS:	FAX:
CITY, STATE, ZIP:	NPI:

PRESCRIBER SIGNATURE: (No stamp signatures)

DATE:

Dispense as written/Brand medically necessary	Substitution permitted
-----------------------------------------------	------------------------